Zydus Cadila has received final approval from the US Food & Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP (US RLD: Nimbex) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial. Cisatracurium Besylate is a nondepolarizing skeletal neuromuscular blocker for intravenous administration. The drug will be manufactured at Liva plant of Cadila Healthcare. The group now has 297 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1528.20 |
Dr. Reddys Lab | 5872.35 |
Cipla | 1405.95 |
Zydus Lifesciences | 997.45 |
Lupin | 1638.40 |
View more.. |